Optimization of conditions for formation and analysis of anti-CD19 FVS191 single-chain Fv homodimer (ScFv')(2)

被引:7
作者
Wang, D
Berven, E
Li, QZ
Uckun, F
Kersey, JH
机构
[1] UNIV MINNESOTA,CTR CANC,BIOTHERAPY INST,MINNEAPOLIS,MN 55455
[2] UNIV MINNESOTA,DEPT LAB MED,MINNEAPOLIS,MN 55455
[3] UNIV MINNESOTA,DEPT PATHOL,MINNEAPOLIS,MN 55455
[4] UNIV MINNESOTA,DEPT PEDIAT,MINNEAPOLIS,MN 55455
[5] UNIV MINNESOTA,DEPT THERAPEUT RADIOL,MINNEAPOLIS,MN 55455
关键词
D O I
10.1021/bc9600776
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In this report, we present the production of a dimeric form of anti-CD19 scFv, the FVS191cys (scFv')(2). Anti-CD19 scFv FVS191cys was constructed by engineering a cysteine residue at the C terminus of the V-L domain of scFv FVS191. FVS191cys (scFv')(2) was formed through a disulfide bond between two FVS191cys molecules. To optimize the yield of FVS191cys (scFv')(2), the effects of oxidation time, buffer pH, and temperature on the formation of dimeric scFv were analyzed. Our study indicates that the formation of FVS191cys (scFv')(2) is oxidation time- and buffer pi-I-dependent; a high pH buffer facilitates the formation of disulfide-linked (scFv')(2). The maximum yield of FVS191cys (scFv')(2) can be achieved when FVS191cys is air-oxidized at 4 degrees C, in buffer with a pH of 8.5-9. The biological activity of FVS191cys (scFv')(2) was analyzed by ELISA and an internalization assay. FVS191cys (scFv)(2) has a CD19 binding ability similar to that of its parental mAb B43 and is internalized by CD19 positive Nalm 6 cells. This study indicates that FVS191cys (scFv')(2) is a potential candidate for tumor diagnosis or therapy.
引用
收藏
页码:64 / 70
页数:7
相关论文
共 22 条
[1]  
ADAMS GP, 1993, CANCER RES, V53, P4026
[2]  
BEJECK BE, 1995, CANCER RES, V55, P2346
[3]   A METHOD FOR INCREASING THE YIELD OF PROPERLY FOLDED RECOMBINANT FUSION PROTEINS - SINGLE-CHAIN IMMUNOTOXINS FROM RENATURATION OF BACTERIAL INCLUSION-BODIES [J].
BUCHNER, J ;
PASTAN, I ;
BRINKMANN, U .
ANALYTICAL BIOCHEMISTRY, 1992, 205 (02) :263-270
[4]   HIGH-LEVEL ESCHERICHIA-COLI EXPRESSION AND PRODUCTION OF A BIVALENT HUMANIZED ANTIBODY FRAGMENT [J].
CARTER, P ;
KELLEY, RF ;
RODRIGUES, ML ;
SNEDECOR, B ;
COVARRUBIAS, M ;
VELLIGAN, MD ;
WONG, WLT ;
ROWLAND, AM ;
KOTTS, CE ;
CARVER, ME ;
YANG, M ;
BOURELL, JH ;
SHEPARD, HM ;
HENNER, D .
BIO-TECHNOLOGY, 1992, 10 (02) :163-167
[5]   INVIVO TUMOR TARGETING OF A RECOMBINANT SINGLE-CHAIN ANTIGEN-BINDING PROTEIN [J].
COLCHER, D ;
BIRD, R ;
ROSELLI, M ;
HARDMAN, KD ;
JOHNSON, S ;
POPE, S ;
DODD, SW ;
PANTOLIANO, MW ;
MILENIC, DE ;
SCHLOM, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (14) :1191-1197
[6]  
CUMBER AJ, 1992, J IMMUNOL, V149, P120
[7]   MULTIMERIZATION BEHAVIOR OF SINGLE-CHAIN FV VARIANTS FOR THE TUMOR-BINDING ANTIBODY B72.3 [J].
DESPLANCQ, D ;
KING, DJ ;
LAWSON, ADG ;
MOUNTAIN, A .
PROTEIN ENGINEERING, 1994, 7 (08) :1027-1033
[8]  
FOON KA, 1989, CANCER RES, V49, P1621
[9]  
JAIN RK, 1987, CANCER RES, V47, P3039
[10]   RECOMBINANT SINGLE-CHAIN FV FRAGMENTS CARRYING C-TERMINAL CYSTEINE RESIDUES - PRODUCTION OF BIVALENT AND BIOTINYLATED MINIANTIBODIES [J].
KIPRIYANOV, SM ;
DUBEL, S ;
BREITLING, F ;
KONTERMANN, RE ;
LITTLE, M .
MOLECULAR IMMUNOLOGY, 1994, 31 (14) :1047-1058